Healthcare Industry News:  Glaucoma 

Biopharmaceuticals Ophthalmology

 News Release - June 7, 2006

InSite Vision Announces the Issuance of an Additional US Patent on Azalide Ophthalmic Products

ALAMEDA, Calif.--(HSMN NewsFeed)--June 7, 2006--InSite Vision Incorporated (AMEX:ISV ) -- an ophthalmic products company currently focused on developing therapies that treat ocular infection, Glaucoma, and retinal diseases, today announced the issuance of an additional US patent on azalide drug products for use in ophthalmology by the United States Patent and Trademark Office (USPTO). Azalides are a class of anti-infective drugs inclusive of azithromycin which is incorporated into InSite Vision's AzaSite(TM) product that recently completed two Phase 3 clinical trials.

"The issuance of this patent further extends and strengthens InSite Vision's intellectual property covering the AzaSite and the AzaSite franchise of products," said S. Kumar Chandrasekaran, Ph.D., InSite Vision's chief executive officer. This patent titled "Topical Treatment or Prevention of Ocular Infections" is a third in a series of issued US patents based on the original patent application filed by InSite Vision covering uses, processes and compositions of azalide antibiotics in ophthalmic indications. The AzaSite product, covered by these series of patents, has successfully completed two Phase 3 clinical trials for the indication of bacterial conjunctivitis and a New Drug Application (NDA) is being prepared which is anticipated for submission to the FDA later this month.

About InSite Vision Incorporated

InSite Vision is an ophthalmic company focused on developing therapies that treat ocular infections, Glaucoma and retinal diseases. InSite Vision's lead product is AzaSite, which targets bacterial infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSiteŽ, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician. Pending the filing and approval of an NDA with the FDA, InSite Vision currently expects AzaSite to be commercially launched in the United States, while seeking to expand this "technology platform" to include additional product candidates and indications for the worldwide market.

In the Glaucoma area, InSite Vision continues to focus genomic research on the TIGR gene, among other genes in its genomic portfolio. A portion of this research has been incorporated into InSite Vision's commercially available OcuGeneŽ Glaucoma genetic test for disease management, which is a prognostic tool designed to detect a genetic marker (mt-1) in the promoter region of the Glaucoma-related TIGR gene.

Additional information can be found at the Company's website, www.insitevision.com.

This news release contains, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision, such as the timing of filing an NDA with the FDA, the Company's ability to obtain FDA approval of its NDA, the anticipated date of commercialization of AzaSite and the Company's plans to expand its technology platform. Such statements entail a number of risks and uncertainties, including but not limited to: InSite Vision's ability to obtain additional financing, InSite Vision's ability to commence, complete and file an NDA with the U.S. FDA for AzaSite, and receive approval from the FDA for the commercialization of AzaSite; InSite Vision's ability to launch AzaSite and the timing of such a launch; InSite Vision's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite and ISV-205; its reliance on third parties for the development, marketing and sale of its products; its ability to adequately protect its intellectual property and to be free to operate with regard to the intellectual property of others, determinations by the FDA, including those with respect to OcuGene, AzaSite and ISV-205. Reference is made to the discussion under the caption "Risk Factors" and elsewhere in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K, and its quarterly reports on Form 10-Q. All forward looking statements in this press release are based on the limited information currently available to InSite Vision, which is subject to change. Although any such projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release and/or conference call is still valid at any later date.

Note to Editors: OcuGeneŽ is written with a "small cap" G; if doing so is not possible, please use an upper case G. InSite Vision Incorporated, InSite Vision, DuraSiteŽ and OcuGeneŽ are trademarks of InSite Vision Incorporated. Other trademarks that may be mentioned in this release are the intellectual property of their respective owners.


Source: InSite Vision

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.